Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Debt / NOTE 2.500% 3/1
-
Market price (% of par)
-
58.89%
-
Total 13F principal
-
$547,874,444
-
Principal change
-
+$8,566,396
-
Total reported market value
-
$329,728,428
-
Number of holders
-
35
-
Value change
-
-$9,335,577
-
Number of buys
-
13
-
Number of sells
-
20
Institutional Holders of BRIDGEBIO PHARMA INC - NOTE 2.500% 3/1 as of Q1 2022
As of 31 Mar 2022,
BRIDGEBIO PHARMA INC - NOTE 2.500% 3/1 was held by
35 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$547,874,444
in principal (par value) of the bond.
The largest 10 bondholders included
ARISTEIA CAPITAL LLC, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), WOLVERINE ASSET MANAGEMENT LLC, LAZARD ASSET MANAGEMENT LLC, HIGHBRIDGE CAPITAL MANAGEMENT LLC, ORBIMED ADVISORS LLC, BNP PARIBAS ARBITRAGE, SA, AVIVA PLC, Davidson Kempner Capital Management LP, and TFG Asset Management GP Ltd.
This page lists
36
institutional bondholders reporting positions
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.